Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.
Lancet Infect Dis
; 16(5): e76-e81, 2016 05.
Article
in En
| MEDLINE
| ID: mdl-27599655
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV-1
/
Reverse Transcriptase Inhibitors
/
Benzoxazines
Type of study:
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Child
/
Humans
Country/Region as subject:
Africa
Language:
En
Journal:
Lancet Infect Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2016
Document type:
Article
Country of publication:
United States